echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Unlock lung squamous cancer "China program" strong to win the first line of treatment.

    Unlock lung squamous cancer "China program" strong to win the first line of treatment.

    • Last Update: 2020-10-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Psalm lung cancer was the leading cause of death (25.2%) of all cancer deaths, with non-small cell lung cancer (NSCLC) accounting for about 80% to 85%.
    about 70% of NSCLC patients were unable to have surgical removal at the time of diagnosis, and 30-60% of NSCLC patients in phase I-III of the treatment surgery eventually relapsed or metas later transferred.
    the past two decades, NSCLC's drug research and development progress has been mainly concentrated in non-scaly NSCLC, which is relatively slow due to its unique epidemiological, hetological and molecular biology characteristics.
    the results of the RECENT ORIENT-12 study offer hope for patients with lung squamous cancer.
    ORIENT-12 study is a randomized, double-blind, Phase III controlled clinical study evaluating the effectiveness and safety of advanced or metastasis Squamount NSCLC first-line treatments in the combined Giesitham and platinum classes of Cindili monoanti or placebo (ClinicalTrials.gov, NCT03629925).
    research endpoints are PFS assessed by the Independent Imaging Review Board (IRRC) on the basis of THECIST v1.1.
    secondary study endpoints include total lifetime (OS), security, and so on.
    A total of 357 subjects in this study were treated with a 1:1 random group of 200 mg or placebo combined gisithamin and platinum, given once every 3 weeks, and after completing 4 or 6 cycles of combined therapy, entered sedili monoanti or placebo maintenance therapy until the disease progressed, toxic impatient or other conditions required to terminate treatment.
    the disease in the control group can be conditioned to cross to Thein Dilli monodrida treatment.
    latest analysis showed that the mid-level PFS assessed by the IRC was significantly longer than in the placebo group, at 5.5 months and 4.9 months, respectively. .00001), the researchers assessed the mid-PFS as 6.7 months and 4.9 months (HR-0.532, P-lt;0.00001), respectively, to reach the preset main study endpoint.
    the two groups did not reach the mid-OS, but there was a benefit trend for the total survival of the Syndicate monoantigroup compared to the total survival of the placebo group (HR=0.567, P=0.01701).
    two groups ≥ similar rates of adverse reactions (86.6% vs 83.1%), no new safety signals were observed.
    the study, PFS improved significantly, with the Syndication monoantigen-GP (Gissitham/Platinum) program reducing the risk of patient progression by more than 40%, and OS improving to some extent, but the data were not yet mature.
    ORIENT-12 study suggests that PD-1 monoantials can be used in a combined way with GP programmes for clinical benefit or as a new option for first-line treatment for advanced lung squamous cancer.
    ORIENT-12 research has gained domestic and international attention, mainly based on the current limited treatment status of scaly NSCLC.
    lung cancer is the world's number one morbidity and mortality rate of tumors.
    as one of the most important pathological types, scaly NSCLC, accounting for about 30% of NSCLC patients in China.
    and similar to the overall lung cancer situation, about 70% of NSCLC patients were diagnosed with locally advanced or metastasis tumors that were not suitable for root surgery.
    treatment, unlike lung adenocarcinoma patients, advanced lung squamous cancer patients EGFR, ALK and other driving gene positive proportion is very low, the traditional mainly in platinum-containing double-drug chemotherapy (yew alcohol / gisitamine / dositamine and platinum).
    the era of immunity, anti-PD-1/PD-L1 antibody drugs have also shown some effectiveness against scaly NSCLC, finding new treatments for scaly NSCLC with limited treatment methods.
    in order to apply the whole population and obtain higher effectiveness, chemotherapy combined immunotherapy has become an important development direction.
    The first-line recommended program for patients with advanced lung squamous cancer in the current NCCN guidelines is Pabli pearl monoantigen and platinum chemotherapy, and paboli pearl monotherapy is recommended for 50% of NSCLC patients with PD-L1 TPS≥
    currently only Paboli pearl monoantigen and yew alcohol approved by the State Drug Administration (NMPA) for first-line treatment of patients with advanced metastatic pulmonary squamous cancer.
    there are still large unsoponsed clinical needs in the field of first-line treatment of scaly NSCLC in China.
    with the success of THET-12 research, scaly NSCLC will usher in a new program.
    believes that more and more new treatment strategies for lung squamous cancer will be made public in the near future.
    source: 1. LBA56 - ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC); 2.; 3.#rdv-calendar.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.